A Randomized, Double-blind, Placebo-controlled, and Multi-center Clinical Study of CM313 in the Treatment of Immune Thrombocytopenia

• Status: Recruiting
• Trial end date: 2026-01-01

Summary

To evaluate the efficacy and safety of CM313 in the treatment of immune thrombocytopenia in patients who have failed glucocorticoid therapy.

• Phase: Phase 2

Details

• Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China
• Collaborators: Henan Cancer Hospital; The Second Affiliated Hospital of Kunming Medical University; Tianjin Medical University Second Hospital; Tianjin People's Hospital